Inogen INC Form 4 insider transactions

Inogen's Chief Commercial Officer, Gregoire Ramade, reported the acquisition of 31,565 shares of common stock and the disposal of 12,942 shares to cover tax obligations, following the vesting of restricted stock units.

Kevin P. Smith, EVP, Bus Dev, GC & Sec of Inogen Inc, acquired 54,406 restricted stock units on July 22, 2024, according to a Form 4 filing with the SEC.

Director Heather D. Rider acquired 21,871 shares of Inogen Inc. common stock through a restricted stock unit award on June 5, 2024.

Director Elizabeth Mora reports changes in beneficial ownership of Inogen Inc. stock, including the acquisition of shares through a restricted stock unit award and the disposal of shares.

Director Glenn S. Boehnlein reports acquiring 21,871 shares of Inogen Inc. common stock through a restricted stock unit award and disposing of 46,273 shares on June 5, 2024.

Director Kevin M. King reports acquiring 21,871 shares and disposing of 46,273 shares of Inogen Inc. common stock on June 5, 2024.

Director Thomas A. West acquired 21,871 shares of Inogen Inc. common stock through a restricted stock unit award on June 5, 2024.

Director Mary Kay Ladone reports acquiring 21,871 shares of Inogen Inc. stock through a restricted stock unit award and disposing of 46,273 shares on June 5, 2024.

Jason Somer, EVP, Gen. Counsel & Secretary of Inogen Inc., reports the acquisition and disposal of common stock and restricted stock units on June 1, 2024, according to a Form 4 filing with the SEC.

Jason Somer, EVP, General Counsel & Secretary of Inogen Inc, sold 10,000 shares of common stock on May 10, 2024, at an average price of $8.56.

Jason Somer, EVP, General Counsel & Secretary of Inogen Inc., reports the acquisition and disposal of Inogen common stock on May 1, 2024, related to the vesting of restricted stock units.

Stanislav Glezer, EVP, R&D & Chief Medical Officer of Inogen Inc, reports the vesting and subsequent tax withholding of shares on May 1, 2024.

Michael J. Bourque, EVP, CFO & Treasurer of Inogen Inc, reports the acquisition of 75,000 restricted stock units on March 4, 2024, according to a Form 4 filing with the SEC.

Jason Somer, EVP, General Counsel & Secretary of Inogen Inc, reports the vesting and disposal of restricted stock units to cover tax obligations.

Inogen CEO Kevin Raymond Merrill Smith was granted 85,000 restricted stock units on March 1, 2024, according to a Form 4 filing with the SEC.

Stanislav Glezer, EVP, R&D & Chief Medical Officer of Inogen Inc., reports the acquisition and disposal of Inogen common stock and restricted stock units on March 1, 2024.